RRML - Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2016): 0.325

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- October 2017 -
 
Effect of long period treatment w... 6
Screening for common cystic fibro... 5
IL-6 gene polymorphisms and sepsi... 5
Association of ischemia-modified ... 5
Association of methionine synthas... 4
Epigenetic changes in myelodyspla... 4
Romanian Review of Laboratory Med... 4
Therapy-related myelodysplastic s... 4
Involvement of inflammatory marke... 4
Effects of low-molecular weight a... 4

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Ahead of print DOI:10.1515/rrlm-2017-0032
XML
TXT

Research article

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Olga Hilda Orăsan, Ljubomir Petrov, Laura Urian, Angela Cozma, George Ciulei, Ioan Mihai Patiu, Remus Aurel Orăsan

Correspondence should be addressed to: Olga Hilda Orăsan

Abstract

Introduction. The study of dialysis patients not needing erythropoiesis-stimulating agents (ESA) for long periods of time has gained interest lately. The aim of this study was to compare laboratory and clinical parameters in hemodialysis patients with autosomal dominant polycystic kidney disease (ADPKD) treated or not with ESA. Methods. Forty-six hemodialysis ADPKD patients were studied for 8 months and they were divided into: group 1- 29 patients who received ESA during the study period and group 2- 17 patients with no ESA treatment. The following parameters were determined: weekly treatment time, body mass index (BMI), pre-session diastolic blood pressure (DBP), pre-session systolic blood pressure (SBP), blood volume processed (BVD), interdialytic body weight gain (IBWG), spKt/V -K/DOQI formula (Kt/V), urea distribution volume (UDV), hemoglobin (Hb), ferritin, transferrin saturation (TSAT), serum phosphate, total serum calcium, normalized protein catabolic ratio (nPCR), albumin, and intact parathormone (PTH). Results. Patients not requiring ESA were more likely to be men, had higher Hb, albumin, total serum calcium levels, IBWG, UDV, BVP, and weekly treatment time. They had lower ferritin, TSAT, SBP. There was no difference regarding DBP, BMI, serum phosphate, PTH, Kt/V, and nPCR. Conclusion. Hemodialysis ADPKD patients not treated with ESA seem to be better nourished, with a slightly better SBP control, with longer dialysis time and increased Hb (despite lower iron loading markers), compared to hemodialysis ADPKD patients treated with ESA.

Keywords: autosomal dominant polycystic kidney disease, erythropoiesis-stimulating agents, anemia, hemodialysis

Received: 23.3.2017
Accepted: 4.9.2017
Published: 6.10.2017

 
  PDF Download full text PDF
(347 KB)